MEMORANDUM

MEMORANDUM
PRIVILEGED & CONFIDENTIAL — ATTORNEY WORK PRODUCT
TO: Marcus Delgado, Responsible Partner, intellectual Property, Calderwood & Harkness LLP
FROM: Peter Vassiliev, Lead Associate, IP; Wendy Schultz, Working Associate, IP
DATE: July 25, 2023
RE: Preliminary Analysis of PPC-4187 (Penteracitinib) Patent Portfolio — Licensing Suitability Assessment
MATTER: Penterra Pharmaceuticals Corp. — Out-License of PPC-4187
CLIENT: Penterra Pharmaceuticals Corp.
Right-click to update Table of Contents
I. Executive Summary
Calderwood & Harkness LLP has been engaged by Penterra Pharmaceuticals Corp. ("Penterra" or "PPC"), a Delaware corporation publicly traded on the Nasdaq Stock Market (ticker: PNTR), headquartered at 400 Pharma Drive, Suite 800, Princeton, New Jersey 08540, in connection with the potential out-licensing of its proprietary small-molecule compound PPC-4187 (proposed International Nonproprietary Name: Penteracitinib), a selective Janus kinase 1 ("JAK1") inhibitor being developed for the treatment of moderate-to-severe atopic dermatitis in adults, to a regional pharmaceutical partner for the Asia-Pacific territory (the "Territory"). The matter was opened on July 10, 2023 under Calderwood & Harkness Matter Number PPC-OL-2023-0042.
This memorandum provides a preliminary assessment of the intellectual property portfolio associated with PPC-4187, with a focus on evaluating the portfolio's suitability and strength for an exclusive out-license transaction covering the Territory. The assessment is based on information provided by Penterra, consultations with patent prosecution counsel, and publicly available patent and trademark records reviewed as of the date of this memorandum. This preliminary analysis is intended to identify the scope, strengths, and potential risks of the portfolio, and to frame the comprehensive diligence work that will follow.
The PPC-4187 intellectual property portfolio is substantial and well-structured. It comprises seven (7) patent families covering composition of matter, crystalline forms, methods of use (treatment of atopic dermatitis), pharmaceutical formulation, manufacturing process, combination therapy methods, and dosage regimen. The portfolio includes multiple granted patents and numerous pending applications across the United States, the People's Republic of China, Japan, the Republic of Korea, Australia, Singapore, and six additional ASEAN jurisdictions. National phase entries in the Territory jurisdictions were derived from international application PCT/US2019/045123, filed in 2019.
In addition to the patent portfolio, Penterra holds trademark registrations and pending applications for the proposed trade name PENTECLAR, which is the brand name under which PPC-4187 would be marketed commercially. Registrations have been obtained or applications filed in the United States, Hong Kong SAR, China, Japan, South Korea, and Australia, with additional filings in other Territory jurisdictions to be confirmed.
Overall Preliminary Conclusion: Based on our initial review, the PPC-4187 intellectual property portfolio appears well-suited for an exclusive territorial out-license covering the Asia-Pacific region. The core composition-of-matter patents have been granted in all major APAC markets, providing approximately fourteen (14) years of remaining patent protection from the date of this memorandum. The layered protection afforded by multiple patent families covering different aspects of the compound, formulation, and methods of use creates a robust defensive position. However, comprehensive diligence is required, including a thorough freedom-to-operate analysis, a detailed review of prosecution file histories, an assessment of third-party patent landscape risks, and a confirmation of the status of all pending applications in the Territory jurisdictions.
Patent prosecution counsel Whitford & Cascade Insurance Brokers (Dr. Alan J. Whitford, 1750 K Street NW, Suite 600, Washington, DC 20006), which has served as Penterra's prosecution counsel since the inception of the PPC-4187 patent program, has been consulted in connection with this preliminary assessment and will be engaged to provide a detailed freedom-to-operate opinion for the licensed Territory as part of the comprehensive diligence phase described in Section IX below.
II. Background
A. The Compound — PPC-4187
PPC-4187, for which the proposed International Nonproprietary Name (INN) is Penteracitinib, is a selective Janus kinase 1 (JAK1) inhibitor designed for oral administration. PPC-4187 was discovered and developed internally by Penterra's medicinal chemistry and drug discovery teams at the company's Princeton, New Jersey research facility. The compound is formulated as a once-daily oral film-coated tablet, which represents a significant convenience advantage for patients with chronic dermatological conditions requiring long-term therapy.
The primary indication for which PPC-4187 is being developed is moderate-to-severe atopic dermatitis in adult patients. Atopic dermatitis is a chronic inflammatory skin condition affecting an estimated 200 million people globally, with substantial unmet medical need despite the introduction of biologics and other JAK inhibitors in recent years. The JAK1-selective mechanism of PPC-4187 is intended to provide targeted anti-inflammatory activity while minimizing the off-target effects associated with broader JAK inhibition.
At the time of this memorandum, PPC-4187 has completed its Phase IIb clinical development in the United States and the European Union. The pivotal Phase IIb trial (Penterra-sponsored Study PPC-4187-201) enrolled 420 patients with moderate-to-severe atopic dermatitis at approximately 65 clinical sites across North America and Europe. Topline results were reported in June 2023 and demonstrated a statistically significant improvement in the primary endpoint — the proportion of patients achieving an EASI-75 response (75% improvement from baseline in the Eczema Area and Severity Index) at Week 16 — compared with placebo, with a p-value of less than 0.001 at both the 25 mg and 50 mg dose levels. Secondary endpoints, including improvement in pruritus (itch) severity and quality-of-life measures, also showed statistically significant improvements. The safety profile observed in Study PPC-4187-201 was generally consistent with the known class effects of JAK inhibitors, with no new or unexpected safety signals identified.
PPC-4187 is being developed in two dosage strengths: 25 mg and 50 mg film-coated tablets. The tablets are manufactured using a validated commercial-scale manufacturing process.
With respect to Chemistry, Manufacturing, and Controls ("CMC") status, the manufacturing process for PPC-4187 active pharmaceutical ingredient ("API") and finished dosage form has been validated at Penterra's contract manufacturing organization, Alkerra Manufacturing Inc., located at 5200 Meridian Parkway, Research Triangle Park, North Carolina 27713. Alkerra has been Penterra's primary CMO for PPC-4187 since the compound entered late-stage preclinical development and has manufactured all clinical trial material used in Studies PPC-4187-101 (Phase I) and PPC-4187-201 (Phase IIb). Alkerra's facility is FDA-inspected and holds current Good Manufacturing Practice ("cGMP") compliance certifications. Technology transfer documentation, including complete batch manufacturing records, process validation protocols and reports, and analytical methods and specifications, is maintained by Penterra in coordination with Alkerra.
B. Penterra Pharmaceuticals Corp.
Penterra Pharmaceuticals Corp. is a Delaware corporation incorporated on March 15, 2008, and publicly traded on the Nasdaq Stock Market under the ticker symbol PNTR (Employer Identification Number: 22-3948175). As of the most recent public filings, Penterra's market capitalization is approximately $2.1 billion, and its fiscal year 2022 annual revenue was $487 million, derived primarily from commercial sales of its marketed dermatology and immunology products. Penterra's corporate headquarters are located at 400 Pharma Drive, Suite 800, Princeton, New Jersey 08540.
Penterra's pipeline comprises 14 compounds in various stages of development, spanning preclinical through Phase III. PPC-4187 is among the company's most advanced pipeline assets and is considered by management to be a cornerstone of Penterra's growth strategy in the dermatology therapeutic area. In addition to PPC-4187, Penterra has three other compounds in Phase II development targeting autoimmune and inflammatory conditions.
The key Penterra personnel relevant to this engagement are as follows:
•  Chief Executive Officer: Dr. Raymond K. Ostrowski
•  General Counsel: Anita M. Fremont, Esq.
•  Vice President, intellectual Property: Dr. Priya Nandakumar
Penterra's Board of Directors authorized the negotiation of an out-license arrangement for PPC-4187 covering the Asia-Pacific territory at a meeting held on July 18, 2023. The Board resolution authorized Dr. Ostrowski and Ms. Fremont to engage external advisors and negotiate definitive transaction documents, subject to final Board approval of the executed agreement. Calderwood & Harkness was formally engaged as transaction counsel for the IP aspects of the out-license on July 10, 2023, in anticipation of the Board authorization, with the initial scope of work focused on the preliminary IP diligence reflected in this memorandum.
C. Contemplated Transaction
The contemplated transaction involves an exclusive out-license of PPC-4187 and associated intellectual property for the Asia-Pacific region to a regional pharmaceutical partner. The identity of the counterparty licensee has not yet been finalized; Penterra and its financial advisor, Prescott Hale & Co. LLC, are currently in discussions with multiple potential licensees and expect to select a preferred partner in the coming weeks.
The Territory for purposes of the contemplated out-license is expected to encompass the following jurisdictions: the People's Republic of China (including Hong Kong SAR and Macau SAR), Japan, the Republic of Korea, Australia, New Zealand, Singapore, Thailand, Malaysia, Indonesia, the Philippines, Vietnam, and Taiwan. The precise definition of the Territory will be subject to negotiation and will be set forth in the definitive license agreement.
Under the contemplated transaction structure, Penterra would retain all rights to PPC-4187 outside the Asia-Pacific territory, including rights in the United States, Canada, the European Union and European Economic Area, the United Kingdom, Latin America, the Middle East, Africa, and all other countries and territories not included in the defined Territory. The license is expected to be exclusive within the Territory, with the licensee receiving the right to develop, register, manufacture (or have manufactured), and commercialize PPC-4187 products within the Territory, subject to appropriate quality control and commercialization obligations.
The suitability and strength of the PPC-4187 intellectual property portfolio is a critical factor in establishing the appropriate licensing value for the out-license transaction. The portfolio assessment will directly inform the structuring of the grant of rights, the definition of licensed patents and licensed know-how, the allocation of prosecution and enforcement obligations, and the negotiation of financial terms including upfront payments, milestone payments, and royalty rates. The preliminary IP diligence reflected in this memorandum is the first step in that assessment process.
III. Patent Portfolio Overview
The PPC-4187 patent portfolio comprises a total of seven (7) patent families, each directed to a distinct aspect of the PPC-4187 compound, formulation, or methods of use. Collectively, these families provide layered intellectual property protection that covers the PPC-4187 molecule itself, its preferred crystalline form, its therapeutic applications, the specific pharmaceutical formulations in which it is delivered, the manufacturing process for its synthesis, combination therapy approaches, and dosing regimens. This multi-layered strategy is consistent with industry best practices for lifecycle management of small-molecule pharmaceutical assets and is designed to maximize the duration and breadth of market exclusivity.
Patent prosecution for the entire PPC-4187 portfolio has been managed by Whitford & Cascade Insurance Brokers, under the direction of Dr. Alan J. Whitford, at the firm's Washington, DC office (1750 K Street NW, Suite 600, Washington, DC 20006). Dr. Whitford has served as Penterra's lead patent prosecution counsel since 2017 and has extensive experience in pharmaceutical patent prosecution before the U.S. Patent and Trademark Office, the Japan Patent Office, the China National intellectual Property Administration, the Korean intellectual Property Office, and IP Australia.
International patent protection for the portfolio has been pursued primarily through the Patent Cooperation Treaty ("PCT") route, with the key international application being PCT/US2019/045123, filed in 2019. National phase entries have been made from this PCT application in Japan, China, the Republic of Korea, Australia, Singapore, and six additional ASEAN countries (Thailand, Malaysia, Indonesia, the Philippines, Vietnam, and a sixth ASEAN jurisdiction to be confirmed). The use of the PCT route has enabled efficient prosecution of corresponding patent applications across multiple jurisdictions simultaneously.
The following subsections provide a family-by-family description of the PPC-4187 patent portfolio, including the current status of granted patents and pending applications in both the United States and the Territory jurisdictions.
A. Patent Family 1 — Composition of Matter
Patent Family 1 is the core patent family in the PPC-4187 portfolio. It protects the PPC-4187 molecule itself — i.e., the chemical compound Penteracitinib, including its free base, pharmaceutically acceptable salts, solvates, hydrates, and prodrugs. Composition-of-matter claims represent the broadest and most commercially valuable form of patent protection for a pharmaceutical compound, as they cover the compound per se, irrespective of formulation, indication, dosage form, or method of use. A competitor cannot make, use, sell, offer to sell, or import the claimed compound during the life of a valid composition-of-matter patent without a license from the patent holder.
The following patents have been granted under Family 1:
All of the above granted patents were derived from national phase entries of PCT/US2019/045123. The uniform expiration date of August 12, 2037 across all jurisdictions reflects the common priority date and the consistent twenty-year patent term measured from the filing date of the underlying application under the patent laws of each jurisdiction.
Analysis: The grant of composition-of-matter patents in all major APAC markets — China, Japan, South Korea, and Australia — is a significant strength of the PPC-4187 portfolio. These four jurisdictions together represent the vast majority of pharmaceutical market value within the contemplated Territory. The August 12, 2037 expiration date provides approximately fourteen (14) years of remaining patent protection from the date of this memorandum, which is sufficient to cover the expected regulatory approval timeline, commercial launch, and a substantial period of market exclusivity in the Territory.
We note that there is potential for patent term extension ("PTE") or equivalent supplementary protection in certain Territory jurisdictions upon receipt of regulatory approval. Japan's patent law provides for patent term extensions of up to five (5) years for pharmaceutical patents where the marketing approval process has consumed a portion of the patent term. Australia similarly provides for patent term extensions of up to five (5) years under the Patents Act 1990. A detailed PTE analysis will be conducted as part of the comprehensive diligence phase once the anticipated regulatory timelines in each Territory jurisdiction are better defined.
B. Patent Family 2 — Crystalline Form
Patent Family 2 is directed to Crystalline Form A of Penteracitinib, which is the specific crystalline polymorph used in the commercial formulation of PPC-4187. Crystalline form patents provide an important additional layer of protection beyond the composition-of-matter claims, as they protect the specific solid-state form of the compound that has been selected for development and commercialization. Competitors seeking to market a generic version of PPC-4187 would likely need to use the same crystalline form to achieve bioequivalence, and a crystalline form patent can therefore serve as an effective barrier to generic entry even after the composition-of-matter patent has expired.
The following patent has been granted under Family 2:
National phase filings derived from PCT/US2019/045123 have been made in Territory jurisdictions, including China, Japan, the Republic of Korea, and Australia. The current examination status of these applications has not yet been confirmed at this preliminary stage; we will request a detailed prosecution status report from Whitford & Cascade Insurance Brokers as part of the comprehensive diligence process.
Analysis: The crystalline form patent extends U.S. protection beyond the composition-of-matter expiry by approximately fourteen (14) months (from August 12, 2037 to November 3, 2038). If corresponding crystalline form patents are successfully prosecuted and granted in the Territory jurisdictions, this extended protection would similarly apply in the key APAC markets. Crystalline Form A is the form used in both the 25 mg and 50 mg film-coated tablet formulations currently in clinical development, and it is the form validated at the Alkerra Manufacturing Inc. facility. The commercial significance of this patent family is therefore directly tied to the marketed product.
We note that crystalline form patents may be vulnerable to challenge by competitors who argue that they can manufacture the compound in a different polymorphic form. However, the practical difficulty of manufacturing a stable alternative polymorph, combined with the regulatory requirement to demonstrate bioequivalence using the same reference product, generally makes crystalline form patents a meaningful deterrent to generic entry in practice.
C. Patent Family 3 — Methods of Use
Patent Family 3 comprises claims directed to methods of treating moderate-to-severe atopic dermatitis by administering PPC-4187 (Penteracitinib) to a patient in need thereof. Methods-of-use patents protect the therapeutic application of the compound rather than the compound itself, and they serve as an important supplemental layer of protection in the pharmaceutical context.
A U.S. patent under Family 3 has been granted, and national phase applications have been filed in key APAC jurisdictions — including China, Japan, the Republic of Korea, Australia, Singapore, and the six additional ASEAN countries — via PCT/US2019/045123. The specific patent numbers, grant dates, and examination status of these applications will be confirmed with Whitford & Cascade Insurance Brokers.
Analysis: Methods-of-use claims supplement the composition-of-matter protection by specifically claiming the therapeutic indication for which PPC-4187 is being developed and marketed. In jurisdictions where the composition-of-matter patent remains in force, these claims provide redundant protection. However, following expiry of the composition-of-matter patent, methods-of-use claims may serve as the primary basis for preventing generic competition for the specific indication of atopic dermatitis, particularly where the generic applicant's product labeling references the patented indication.
We note that the enforceability of methods-of-use (or "method-of-treatment") claims varies significantly across the Territory jurisdictions. In particular:
•  China: Chinese patent law does not permit the enforcement of method-of-treatment claims against physicians prescribing or administering a treatment. However, such claims may be enforceable against manufacturers who produce and market a product specifically indicated for the patented method of treatment, particularly under the evolving patent linkage system introduced by the 2020 amendments to the PRC Patent Law.
•  Japan: Methods-of-use claims are generally enforceable in Japan and are a well-established form of pharmaceutical patent protection. The Japan Patent Office has a well-developed examination framework for assessing the novelty and inventive step of method-of-use claims.
•  Republic of Korea: Methods-of-use claims are recognized and enforceable in South Korea, subject to standard validity requirements.
•  Australia: Methods-of-use claims are enforceable under Australian patent law, although the patent specification must clearly define the method and the therapeutic application.
•  ASEAN Jurisdictions: Enforceability varies significantly. Some ASEAN jurisdictions have limited experience adjudicating pharmaceutical method-of-use patent disputes, and the practical enforceability of such claims may be uncertain.
A jurisdiction-by-jurisdiction enforceability analysis will be included in the comprehensive diligence report.
D. Patent Family 4 — Pharmaceutical Formulation
Patent Family 4 encompasses claims covering the specific pharmaceutical formulations of PPC-4187, including the film-coated tablet formulations in 25 mg and 50 mg dosage strengths. The claims are directed to the specific excipient compositions used in the tablet core and film coating, as well as stability-enhancing features of the formulation, including the selection of specific stabilizers, disintegrants, and coating polymers that provide the product with acceptable shelf life and dissolution characteristics.
A U.S. patent under Family 4 has been granted. National phase applications have been filed in Territory jurisdictions via PCT/US2019/045123, and their examination status is pending confirmation.
Analysis: Formulation claims protect the specific marketed dosage forms and may serve as a meaningful deterrent to generic competition, particularly where a generic manufacturer seeks to develop a bioequivalent product using the same formulation approach. Generic applicants frequently rely on the innovator's formulation as a starting point, and formulation patents can compel competitors to develop alternative formulations, which may entail additional development time and regulatory risk. The practical significance of formulation patents is particularly high in jurisdictions where composition-of-matter patents have expired or are nearing expiry, as the formulation patent may then serve as the primary barrier to generic entry.
We note that formulation patents are generally considered to provide narrower protection than composition-of-matter patents, as competitors can potentially design around the specific claimed formulation. Nevertheless, the inclusion of formulation patents in the portfolio adds an important supplemental layer of protection and increases the overall strength of the intellectual property position supporting the out-license.
E. Patent Family 5 — Manufacturing Process
Patent Family 5 is directed to the synthetic route and key process steps used in the manufacture of PPC-4187 active pharmaceutical ingredient. The claims cover the specific chemical synthesis pathway, including intermediates, reagents, reaction conditions, and purification steps that have been developed and optimized by Penterra's process chemistry team and validated at Alkerra Manufacturing Inc.
A U.S. patent under Family 5 has been granted. National phase applications have been filed in Territory jurisdictions via PCT/US2019/045123, with examination status pending confirmation.
Analysis: Process patents complement composition-of-matter protection by covering the method of manufacturing the compound. While process patents are generally considered to be narrower in scope than composition-of-matter patents — because competitors can potentially develop alternative synthetic routes — they nonetheless provide valuable protection, particularly in jurisdictions that have strong patent enforcement mechanisms for process claims and that impose the burden on alleged infringers to demonstrate that their process differs from the patented process.
In the context of the contemplated out-license transaction, the manufacturing process patents have particular relevance to the technology transfer obligations that would be included in the license agreement. The licensee will require access to the validated manufacturing process in order to establish local manufacturing capability or engage a contract manufacturer in the Territory. The process patents both protect the proprietary manufacturing know-how and provide a legal framework for controlling the licensee's use of that technology. The technology transfer provisions of the license agreement should be closely coordinated with the scope of the process patent claims.
F. Patent Family 6 — Combination Therapy Methods
Patent Family 6 comprises claims directed to methods of treating atopic dermatitis using PPC-4187 in combination with one or more additional therapeutic agents, including topical corticosteroids (such as triamcinolone acetonide and betamethasone valerate), calcineurin inhibitors (such as tacrolimus and pimecrolimus), and other agents commonly used in the management of atopic dermatitis. Combination therapy approaches are frequently employed in clinical practice for moderate-to-severe atopic dermatitis, and claims covering such combinations may provide additional commercial value by protecting the manner in which PPC-4187 is most commonly prescribed and used.
Applications under Family 6 have been filed in the United States and in select APAC jurisdictions. Examination is ongoing in all jurisdictions, and no patents have been granted under this family as of the date of this memorandum.
Analysis: Combination therapy claims may provide additional commercial value and extend the effective period of market exclusivity, particularly as clinical practice guidelines evolve and combination regimens become standard of care for the target indication. However, the prosecution status and ultimate grant prospects for these claims remain to be determined. We will request a detailed prosecution status update from Whitford & Cascade Insurance Brokers as part of the comprehensive diligence process. We also note that the enforceability of combination therapy method claims is subject to the same jurisdictional considerations discussed above in connection with Patent Family 3 (Methods of Use), including the limitations on enforceability of method-of-treatment claims in China and certain ASEAN markets.
G. Patent Family 7 — Dosage Regimen
Patent Family 7 is directed to specific dosing schedules for PPC-4187, including once-daily administration protocols, dose titration regimens (e.g., initiation at 25 mg once daily with escalation to 50 mg once daily), and maintenance dosing protocols. Dosage regimen patents have become an increasingly important component of pharmaceutical patent portfolios, as they protect the specific manner of administration that has been clinically validated and is reflected in the approved product labeling.
Applications under Family 7 have been filed in the United States and in select APAC jurisdictions, and prosecution is ongoing.
Analysis: Dosage regimen claims can provide supplemental protection, particularly in the later stages of a product's lifecycle when composition-of-matter and formulation patents may be nearing expiry. However, the enforceability of dosage regimen claims varies by jurisdiction and is subject to similar considerations as methods-of-use claims, particularly in China and certain ASEAN markets where method-of-treatment claims face enforceability challenges. Additionally, some jurisdictions may view dosage regimen claims skeptically if the claimed dosing schedule is considered obvious in light of the prior art or the general knowledge of the skilled person. The prosecution and enforceability outlook for Family 7 will be assessed in detail during the comprehensive diligence phase.
IV. Patent Portfolio — Jurisdiction-by-Jurisdiction Summary for Contemplated Territory
This section provides a jurisdiction-by-jurisdiction summary of the PPC-4187 patent portfolio status in each country or territory encompassed by the contemplated Territory, together with key regulatory and enforcement considerations relevant to the out-license transaction.
A. People's Republic of China (including Hong Kong SAR and Macau SAR)
Patent Status:
•  Granted: CN Patent No. ZL 2020 1 0456789.0 — Composition of Matter (Penteracitinib); granted by the China National intellectual Property Administration ("CNIPA"); expires August 12, 2037.
•  Pending: Applications for crystalline form (Family 2), methods of use (Family 3), pharmaceutical formulation (Family 4), manufacturing process (Family 5), combination therapy (Family 6), and dosage regimen (Family 7) have been filed via national phase entry from PCT/US2019/045123. Current examination status to be confirmed with Whitford & Cascade Insurance Brokers.
Key Considerations:
China represents the single largest pharmaceutical market within the contemplated Territory, with annual pharmaceutical sales exceeding $170 billion and robust growth in the specialty dermatology segment. The strength of the PPC-4187 patent position in China is therefore of paramount importance to the value of the out-license.
The recent amendments to the PRC Patent Law, which took effect on June 1, 2021, introduced several provisions of significant relevance to pharmaceutical patent holders, including: (i) a patent linkage system for pharmaceutical products, similar in concept to the U.S. Hatch-Waxman framework, which provides innovators with an early resolution mechanism for patent disputes arising from generic drug applications; (ii) patent term compensation of up to five (5) years for new drug patents to offset regulatory review delays; and (iii) enhanced remedies for patent infringement, including increased damages and preliminary injunctions.
The enforceability of methods-of-treatment claims in China remains a nuanced area. While Chinese patent law does not permit the direct enforcement of method-of-treatment claims against healthcare practitioners, there is growing jurisprudence and administrative practice supporting the enforcement of such claims against pharmaceutical manufacturers whose products are specifically indicated for the patented method of treatment. The evolving patent linkage system is expected to further strengthen the enforceability of pharmaceutical patents in China, including method-of-use claims, in the coming years.
Regarding Hong Kong SAR and Macau SAR, separate patent registration or extension procedures apply. Hong Kong operates a re-registration system under the Patents (Short-term) Ordinance and the Patents Ordinance, while Macau has its own patent registration regime. The status of any patent filings in Hong Kong and Macau will be confirmed with Whitford & Cascade Insurance Brokers.
The National Medical Products Administration ("NMPA") administers pharmaceutical regulatory approvals in China. Regulatory data protection of up to six (6) years may be available for innovative drug products, which would supplement patent-based exclusivity. The interaction between regulatory data protection and patent protection will be analyzed in the comprehensive diligence report.
B. Japan
Patent Status:
•  Granted: JP Patent No. 7,012,345 — Composition of Matter (Penteracitinib); granted by the Japan Patent Office ("JPO"); expires August 12, 2037.
•  Pending: Applications for crystalline form (Family 2) and other family applications have been filed via national phase entry from PCT/US2019/045123. Current examination status to be confirmed.
Key Considerations:
Japan is the second-largest pharmaceutical market in the Territory and the third-largest in the world, with annual pharmaceutical expenditure exceeding $85 billion. The Japanese market is characterized by a well-established regulatory framework, a strong intellectual property enforcement regime, and a sophisticated generic pharmaceutical industry that is actively expanding in response to government policies encouraging generic substitution.
Japan's patent term extension regime is particularly favorable for pharmaceutical patent holders. Under the Japanese Patent Act, a patent term extension of up to five (5) years may be granted where the patent holder was unable to work the patented invention due to the time required to obtain regulatory approval from the Pharmaceuticals and Medical Devices Agency ("PMDA"). If a patent term extension of the maximum five years is obtained for JP Patent No. 7,012,345, the effective expiration date of the composition-of-matter patent in Japan could be extended to as late as August 12, 2042, providing approximately nineteen (19) years of patent protection from the date of this memorandum. The precise duration of any extension will depend on the time elapsed between the patent filing date and the date of marketing approval in Japan.
The JPO is widely regarded as having a high-quality examination process, and patents granted by the JPO are generally considered to be robust. Methods-of-use claims and dosage regimen claims are enforceable in Japan, and the Japanese courts have a well-developed body of case law addressing pharmaceutical patent disputes.
C. Republic of Korea
Patent Status:
•  Granted: KR Patent No. 10-2345678 — Composition of Matter (Penteracitinib); granted by the Korean intellectual Property Office ("KIPO"); expires August 12, 2037.
•  Pending: Applications for additional patent families have been filed via national phase entry from PCT/US2019/045123. Current examination status to be confirmed.
Key Considerations:
South Korea is a significant pharmaceutical market within the Territory, with annual pharmaceutical expenditure exceeding $20 billion and a rapidly growing biologics and specialty pharmaceuticals sector. The Korean market is characterized by a comprehensive patent linkage system, administered under the Pharmaceutical Affairs Act, which provides innovator patent holders with mechanisms to delay generic market entry pending resolution of patent disputes.
The Ministry of Food and Drug Safety ("MFDS") administers pharmaceutical regulatory approvals in South Korea. The patent linkage system requires generic applicants to notify the innovator of their abbreviated new drug applications and provides for administrative stays and court proceedings to resolve patent disputes prior to generic launch. This system is an important enforcement tool for pharmaceutical patent holders in Korea.
The Korean intellectual Property Office conducts thorough patent examinations, and methods-of-use, formulation, and process claims are generally enforceable in Korean courts. Patent term extensions are available under Korean patent law for pharmaceutical patents, similar to the regimes in Japan and Australia, although the specific provisions and maximum extension periods differ.
D. Australia
Patent Status:
•  Granted: AU Patent No. 2020234567 — Composition of Matter (Penteracitinib); granted by IP Australia; expires August 12, 2037.
•  Pending: Applications for additional patent families have been filed via national phase entry from PCT/US2019/045123. Current examination status to be confirmed.
Key Considerations:
Australia represents a well-developed pharmaceutical market with annual pharmaceutical expenditure exceeding $17 billion and a transparent regulatory framework administered by the Therapeutic Goods Administration ("TGA"). The TGA provides regulatory data protection for a period of five (5) years for new active ingredients, which would supplement the patent-based exclusivity for PPC-4187 in the Australian market.
Australian patent law provides for patent term extensions of up to five (5) years under Part 3 of Chapter 6 of the Patents Act 1990, where the effective patent life has been reduced by the time required to obtain regulatory approval. If the maximum five-year extension is obtained for AU Patent No. 2020234567, the effective expiration date in Australia could extend to as late as August 12, 2042.
Australia has a well-functioning patent litigation system, with the Federal Court of Australia serving as the primary forum for pharmaceutical patent disputes. The Australian courts have extensive experience adjudicating pharmaceutical patent cases, including disputes involving composition-of-matter, formulation, and methods-of-use claims. Interlocutory injunctions are available in appropriate cases, and damages or an account of profits may be awarded for proven infringement.
E. Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Taiwan
Patent Status:
National phase entries from PCT/US2019/045123 have been filed in Singapore and six additional ASEAN markets (including Thailand, Malaysia, Indonesia, the Philippines, and Vietnam). The specific patent numbers, filing dates, and current examination status of these applications have not yet been confirmed at this preliminary stage and will be verified with Whitford & Cascade Insurance Brokers during the comprehensive diligence process. The status of filings in Taiwan (which is not a member of the PCT and requires separate direct filing) will also be confirmed.
Key Considerations:
The ASEAN pharmaceutical markets represent a substantial and growing opportunity, with combined annual pharmaceutical expenditure exceeding $40 billion and strong projected growth driven by expanding healthcare access, rising middle-class populations, and increasing government healthcare spending. However, the patent examination capacity, prosecution timelines, and enforcement infrastructure vary significantly across these jurisdictions.
•  Singapore has a well-developed intellectual property system, with the intellectual Property Office of Singapore ("IPOS") conducting examinations or accepting international search and examination reports. Singapore's courts are experienced in IP litigation, and patent enforcement is generally effective.
•  Thailand has made significant progress in strengthening its patent system, although prosecution timelines remain lengthy and enforcement can be challenging. The Department of intellectual Property conducts patent examinations with increasing sophistication.
•  Malaysia has a functional patent system, and the intellectual Property Corporation of Malaysia ("MyIPO") processes national phase entries from PCT applications. Patent enforcement is available through the courts, although experience with pharmaceutical patent disputes is more limited than in developed markets.
•  Indonesia represents the largest pharmaceutical market in ASEAN, but patent prosecution timelines can be extended and enforcement mechanisms are still developing. The Directorate General of intellectual Property handles patent examinations.
•  The Philippines has a patent system that accepts PCT national phase entries, and the intellectual Property Office of the Philippines ("IPOPHL") has been working to improve examination capacity and reduce backlogs.
•  Vietnam has an evolving intellectual property landscape, with the National Office of intellectual Property ("NOIP") processing patent applications. Vietnam's accession to the Comprehensive and Progressive Agreement for Trans-Pacific Partnership ("CPTPP") has driven significant IP law reforms.
In several of these jurisdictions, the acceptance of PCT international search reports or examination results from major patent offices (e.g., JPO, IP Australia) may facilitate the prosecution process. Some ASEAN jurisdictions also participate in the ASEAN Patent Examination Co-operation ("ASPEC") program, which allows applicants to leverage search and examination results from participating offices.
The practical enforceability of pharmaceutical patents, and particularly methods-of-use and dosage regimen claims, varies significantly across ASEAN. In jurisdictions with limited patent litigation experience, enforcement may depend heavily on administrative mechanisms and regulatory linkage provisions where available.
F. New Zealand
Patent Status:
The status of a national phase entry or direct filing for PPC-4187 patents in New Zealand has not yet been confirmed. New Zealand is included within the contemplated Territory, and patent protection in this jurisdiction should be pursued if not already in place.
Key Considerations:
New Zealand has a well-established pharmaceutical regulatory framework administered by Medsafe (the New Zealand Medicines and Medical Devices Safety Authority). The TGA/Medsafe mutual recognition agreement may facilitate the regulatory approval process. New Zealand's patent examination is handled by the intellectual Property Office of New Zealand ("IPONZ"), which has an agreement with IP Australia under which certain examination functions may be shared. Patent enforcement is available through the New Zealand High Court.
New Zealand's annual pharmaceutical market is relatively modest in size compared to the major APAC jurisdictions, but it represents an important component of a comprehensive regional out-license and is frequently included in Australia-New Zealand territorial packages.
V. Trademark Portfolio — PENTECLAR
Penterra has adopted PENTECLAR as the proposed trade name under which PPC-4187 (Penteracitinib) would be marketed commercially. The PENTECLAR trademark portfolio includes the following registrations and applications:
The specific registration or application numbers, filing dates, and current status of the trademark filings in Hong Kong, China, Japan, South Korea, and Australia will be confirmed with Penterra's IP team (Dr. Priya Nandakumar). In addition, the status of any trademark filings in additional Territory jurisdictions — including Singapore, Thailand, Malaysia, Indonesia, the Philippines, Vietnam, Taiwan, and New Zealand — will be verified as part of the comprehensive diligence process.
Preliminary Assessment: PENTECLAR appears to be a coined or fanciful term without obvious descriptiveness issues. Coined marks are generally entitled to the broadest scope of trademark protection, as they are inherently distinctive and do not describe any quality, characteristic, or function of the goods with which they are used. This is a favorable characteristic for purposes of obtaining and maintaining trademark registrations across multiple jurisdictions.
However, comprehensive trademark clearance searches in all Territory jurisdictions have not yet been completed. There is a possibility that prior third-party registrations or applications for similar marks in pharmaceutical or related classes may exist in one or more Territory jurisdictions. The completion of trademark clearance searches is included as a recommended next step in Section IX below. We note that trademark clearance in certain APAC markets, particularly China and certain ASEAN jurisdictions, requires careful attention to both word marks and Chinese-character transliterations or equivalents of the PENTECLAR mark, as local consumers may identify the product by its Chinese-language name.
Licensing Considerations: If the out-license transaction is completed, a separate Trademark License Agreement (or trademark provisions included within the master License Agreement) will be necessary to grant the licensee rights to use the PENTECLAR mark in the Territory. Such agreement must include appropriate quality control provisions to protect the integrity and goodness of the mark, including requirements that the licensee comply with Penterra's brand guidelines, trademark usage standards, and product quality specifications. Failure to include adequate quality control provisions in a trademark license may result in a "naked license," which can jeopardize the validity and enforceability of the trademark. The trademark licensing provisions will be drafted and negotiated as part of the definitive transaction documentation.
VI. Know-How and Data Assets
In addition to the patent and trademark portfolio, Penterra possesses a substantial body of proprietary know-how, trade secrets, and data assets relating to PPC-4187 that will constitute a critical component of the license grant and technology transfer in the contemplated out-license transaction. These assets include, without limitation, the following:
1.  Proprietary Manufacturing Process Documentation: Complete documentation of the validated manufacturing process for PPC-4187 active pharmaceutical ingredient and finished dosage form, including batch manufacturing records, process validation protocols and reports, process flow diagrams, equipment specifications, and in-process testing procedures. This documentation reflects the manufacturing process developed by Penterra and validated at Alkerra Manufacturing Inc., 5200 Meridian Parkway, Research Triangle Park, NC 27713.
2.  Analytical Methods and Specifications: Validated analytical methods for identity, purity, potency, and dissolution testing of PPC-4187 API and finished dosage form, including HPLC methods, spectroscopic methods, and physical characterization methods. Specifications for release testing and stability testing are included.
3.  Pre-Clinical Data Packages: Comprehensive pre-clinical data, including pharmacology studies (in vitro and in vivo efficacy studies demonstrating JAK1 selectivity and anti-inflammatory activity), toxicology studies (single-dose and repeat-dose toxicity, genotoxicity, carcinogenicity, reproductive toxicity), and ADME (absorption, distribution, metabolism, and excretion) studies.
4.  Clinical Data Packages: Complete clinical data packages from Penterra-sponsored clinical trials, including the full Study PPC-4187-201 database (Phase IIb, 420 patients, randomized double-blind placebo-controlled, EASI-75 at Week 16 primary endpoint). The clinical data package also includes data from the Phase I study (PPC-4187-101), including pharmacokinetic, safety, and tolerability data from healthy volunteers and patients.
5.  Stability Data: Long-term, intermediate, and accelerated stability data for PPC-4187 API and finished dosage form, conducted in accordance with ICH Q1A(R2) guidelines. Stability data supporting the proposed shelf life and storage conditions for the commercial product.
6.  CMC Documentation: Complete Chemistry, Manufacturing, and Controls documentation, including Module 3 of the Common Technical Document ("CTD"), as prepared for regulatory submissions in the United States and European Union. This documentation includes drug substance characterization, drug product formulation development, manufacturing process descriptions, container closure system information, and reference standards.
These know-how and data assets are essential to the licensee's ability to conduct regulatory filings, establish manufacturing capability, and commercialize PPC-4187 in the Territory. The license agreement must include comprehensive provisions governing the transfer, use, protection, and return or destruction of these proprietary assets, including:
•  Strict confidentiality obligations binding the licensee and its employees, agents, and sublicensees;
•  Use restrictions limiting the licensee's use of the know-how and data to the licensed field and territory;
•  Provisions prohibiting the licensee from filing patent applications claiming Penterra's proprietary know-how without Penterra's prior written consent;
•  Return or destruction obligations upon termination or expiration of the license agreement; and
•  Appropriate remedies for breach, including injunctive relief and indemnification.
The technology transfer process will need to be carefully planned and documented. We recommend that the license agreement include a detailed Technology Transfer Plan as a schedule, specifying the timeline, milestones, deliverables, and responsibilities of each party for the transfer of manufacturing process knowledge, analytical methods, and clinical data.
VII. Preliminary Observations on Licensing Suitability
A. Strengths
Based on our preliminary review, the PPC-4187 intellectual property portfolio exhibits several significant strengths that support its suitability for an exclusive territorial out-license:
1.  Core Composition-of-Matter Patents Granted in All Major APAC Markets. The grant of composition-of-matter patents in the United States (U.S. Patent No. 11,234,567), China (CN Patent No. ZL 2020 1 0456789.0), Japan (JP Patent No. 7,012,345), South Korea (KR Patent No. 10-2345678), and Australia (AU Patent No. 2020234567) provides the broadest and most commercially valuable form of patent protection in all four major pharmaceutical markets within the contemplated Territory. The uniform expiration date of August 12, 2037 across these jurisdictions provides approximately fourteen (14) years of remaining patent protection, which is a substantial period of exclusivity.
2.  Crystalline Form Patent Extends Protection Beyond Composition-of-Matter Expiry. The granted U.S. crystalline form patent (U.S. Patent No. 11,345,678) extends protection to November 3, 2038, approximately fourteen months beyond the composition-of-matter expiry. If corresponding crystalline form patents are granted in the Territory jurisdictions, this extended protection could provide an important additional period of market exclusivity during which generic competition would be constrained. Given that Crystalline Form A is the specific polymorph used in the commercial product, the practical significance of this extension is high.
3.  Multiple Patent Families Create Layered Protection. The portfolio's seven (7) patent families — covering composition of matter, crystalline form, methods of use, pharmaceutical formulation, manufacturing process, combination therapy, and dosage regimen — create a comprehensive, multi-layered defensive position. This layered approach is consistent with pharmaceutical industry best practices for lifecycle management and significantly increases the difficulty and cost for potential generic competitors seeking to enter the market. Each additional layer of protection represents a separate legal barrier that a generic competitor must navigate, either by designing around the claims or by successfully challenging the validity of the patent.
4.  Strong Clinical Data Supporting Commercial Value. The Phase IIb clinical data from Study PPC-4187-201 (420 patients; statistically significant improvement vs. placebo with p<0.001 at the EASI-75 primary endpoint at Week 16) provides a strong evidentiary foundation for the commercial potential of PPC-4187. Strong clinical data enhances the value of the intellectual property portfolio by confirming that the protected compound has demonstrated clinical efficacy and is likely to receive regulatory approval, thereby making the patent protection commercially meaningful.
5.  Validated Manufacturing Process with Established CMO. The validation of the PPC-4187 manufacturing process at Alkerra Manufacturing Inc. provides a clear and well-documented pathway for technology transfer to the licensee or the licensee's designated contract manufacturer in the Territory. A validated manufacturing process reduces the development risk associated with the out-license and facilitates the regulatory submission process in Territory jurisdictions.
6.  Trademark PENTECLAR Registered or Filed in Key Territory Jurisdictions. The existence of trademark registrations or applications for PENTECLAR in the United States, Hong Kong, China, Japan, South Korea, and Australia provides a brand identity that can be licensed to the Territory partner, enhancing the commercial value of the out-license package.
B. Areas Requiring Further Diligence
Notwithstanding the strengths identified above, several areas require further investigation during the comprehensive diligence phase:
1.  Freedom-to-Operate Analysis. A comprehensive freedom-to-operate ("FTO") analysis covering all Territory jurisdictions is essential to confirm that the manufacture, use, sale, offer for sale, and importation of PPC-4187 products in the Territory would not infringe any valid and enforceable third-party patent rights. Whitford & Cascade Insurance Brokers (Dr. Alan J. Whitford) has been identified to provide this opinion, and the FTO analysis should be commissioned as a priority item. An adverse FTO finding could materially impact the structure and value of the out-license.
2.  Third-Party Patent Landscape. The JAK inhibitor therapeutic class is highly competitive, with multiple pharmaceutical companies developing JAK1, JAK1/2, and pan-JAK inhibitors for dermatological and other indications. Key competitors in the JAK inhibitor space include, among others, the approved products upadacitinib (Penrose & Co.) and abrocitinib (Ashbury Industries), as well as multiple compounds in clinical development. The third-party patent landscape in this competitive field must be carefully analyzed to identify potential infringement risks, design-around requirements, and potential for patent assertion by competitors or non-practicing entities.
3.  Prosecution Status of Pending Applications in ASEAN. The status of pending patent applications in Singapore and the six additional ASEAN jurisdictions is currently unconfirmed. Prosecution timelines and grant prospects in these jurisdictions may be uncertain, and there is a risk that some applications may not result in granted patents. The comprehensive diligence report should include a jurisdiction-by-jurisdiction assessment of prosecution status, outstanding office actions, and projected timelines for grant.
4.  Patent Term Extension Potential. The potential for patent term extensions in Japan, Australia, and other Territory jurisdictions upon regulatory approval should be analyzed in detail. Patent term extensions can significantly enhance the effective exclusivity period and therefore the commercial value of the licensed intellectual property. The PTE analysis should account for the anticipated regulatory submission and approval timelines in each Territory jurisdiction.
5.  Enforceability of Methods-of-Use and Dosage Regimen Claims. As discussed in Sections III.C and III.G above, the enforceability of methods-of-use and dosage regimen claims varies by jurisdiction, with particular uncertainty in China and certain ASEAN markets. A detailed analysis of the enforceability of these claims in each Territory jurisdiction is necessary to accurately assess the portfolio's protective scope.
6.  Trademark Clearance in Additional Jurisdictions. Trademark clearance searches for PENTECLAR have not yet been completed in all Territory jurisdictions, particularly in the ASEAN countries, Taiwan, and New Zealand. These searches should be completed to confirm that the PENTECLAR mark is available for use and registration throughout the Territory.
7.  Existing Encumbrances and Prior Licenses. Penterra should confirm whether any existing encumbrances, liens, security interests, or prior license agreements affect any portion of the PPC-4187 intellectual property portfolio. The existence of any such encumbrances could limit Penterra's ability to grant an exclusive license in the Territory and must be identified and addressed prior to execution of the definitive license agreement.
C. Structural Considerations for License Agreement
Based on our preliminary assessment of the portfolio, we offer the following structural observations for the license agreement:
1.  Licensed Patents Schedule. The license agreement should include a comprehensive schedule listing all patents and patent applications in all seven (7) families, organized by jurisdiction, with detail including patent numbers, application numbers, filing dates, grant dates, expiration dates, and current prosecution status. The schedule should include a mechanism for regular updating to reflect new grants, new filings, and changes in prosecution status during the term of the agreement.
2.  Licensed Know-How Definition. The definition of "Licensed Know-How" should be drafted comprehensively to cover all proprietary information necessary for the development, regulatory approval, manufacture, and commercialization of PPC-4187 in the Territory, including clinical data, manufacturing process documentation, analytical methods, stability data, CMC documentation, and any future data generated by Penterra.
3.  Patent Prosecution and Maintenance Obligations. The license agreement should allocate responsibility for patent prosecution, maintenance (including payment of annuities and renewal fees), and defense between Penterra (as licensor) and the licensee. We recommend the establishment of a Joint Patent Committee with representatives from both parties to coordinate prosecution and maintenance activities, share information regarding office actions and examination proceedings, and make joint decisions regarding prosecution strategy in the Territory.
4.  IP Infringement Indemnity. The license agreement should address Penterra's indemnification obligations with respect to intellectual property infringement claims arising from the licensee's exercise of the licensed rights. The scope of this indemnity, including any limitations, caps, baskets, and carve-outs, will be a significant point of negotiation. Standard provisions would typically include indemnification for third-party claims that the licensed IP infringes a third party's intellectual property rights in the Territory, subject to appropriate limitations.
5.  Technology Transfer Timeline. The technology transfer timeline should be aligned with the anticipated regulatory submission schedule in the Territory jurisdictions. A phased technology transfer approach may be appropriate, with initial transfer of regulatory data and clinical information followed by transfer of manufacturing process know-how upon selection of the licensee's designated manufacturing site.
6.  Sublicensing Provisions. If the licensee is permitted to sublicense any portion of the licensed rights (e.g., to local distributors or manufacturing partners in specific Territory jurisdictions), the sublicense provisions should require flow-down of all material IP protections, including confidentiality obligations, use restrictions, quality control requirements, and reporting obligations. Penterra should retain the right to approve any proposed sublicensees.
VIII. Identified IP Risks (Preliminary)
Based on our preliminary review, we have identified the following intellectual property risks that should be further evaluated during the comprehensive diligence phase:
Third-Party Patent Assertion Risk. The JAK inhibitor therapeutic class is a highly active area of pharmaceutical research and development, with numerous companies holding patents on JAK inhibitor compounds, formulations, methods of use, and manufacturing processes. There is a meaningful risk that one or more third parties may assert patent infringement claims against PPC-4187 products in one or more Territory jurisdictions. This risk underscores the critical importance of the comprehensive FTO analysis to be conducted by Whitford & Cascade Insurance Brokers. Without a thorough FTO analysis, Penterra cannot provide adequate assurances to the licensee regarding the freedom to operate in the Territory, and the licensee is unlikely to agree to the commercial terms of the out-license without such assurances.
Varying Patent Enforcement Environments. The enforceability of pharmaceutical patents varies significantly acro